3 May 2023
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Notice of Results and Investor Presentation
Ondine Biomedical Inc. (AIM: OBI) announces that it will publish its audited results for the year ended 31 December 2022 ("Full Year Results") on 10th May 2023. Dr. Nicolas Loebel, President and Chief Technology Officer of the Company, will provide a live presentation relating to the Full Year Results via Investor Meet Company at 4:30 pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00 am BST the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet ONDINE BIOMEDICAL INC. via: https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor
Investors who already follow ONDINE BIOMEDICAL INC. on the Investor Meet Company platform will automatically be invited.
A full overview of the 2022 fiscal year will be presented in our upcoming Annual Report 2022, which will be posted to shareholders in due course, will be available on the Company's website:
www.ondinebio.com/investors/reports-documentation/.
| Ondine Biomedical Inc. |
|
| Angelika Vance, Corporate Communications | +001 (1) 604 838 2702 |
|
|
|
| Singer Capital Markets (Nominated Adviser and Joint Broker) |
|
| Aubrey Powell, Asha Chotai, Sam Butcher | +44 (0)20 7496 3000 |
|
|
|
| RBC Capital Markets (Joint Broker) |
|
| Rupert Walford, Kathryn Deegan | +44 (0) 20 7653 4000 |
|
|
|
| Vane Percy & Roberts (Media Contact) |
|
| Simon Vane Percy, Amanda Bernard | +44 (0) 77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave™. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
